The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials

Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2014-09, Vol.111 (6), p.1122-1131
Main Authors: Segelov, E, Chan, D, Shapiro, J, Price, T J, Karapetis, C S, Tebbutt, N C, Pavlakis, N
Format: Article
Language:English
Subjects:
692/699/67/1059/99
692/699/67/1504/1885
692/700/565/1331
Angiogenesis
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
Biological Therapy - adverse effects
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Chemotherapy
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Confidence intervals
Data analysis
Disease-Free Survival
Drug Resistance
Epidemiology
ErbB Receptors - antagonists & inhibitors
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Immunotherapy
Medical sciences
Meta-analysis
Metastasis
Molecular Medicine
Monoclonal antibodies
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Oncology
Patients
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Response rates
Review
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Systematic review
Toxicity
Tumors
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2014.404